# First-in-Human Study With GNbAC1 in Healthy Volunteers

> **NCT01699555** · PHASE1 · COMPLETED · sponsor: **GeNeuro Innovation SAS** · enrollment: 33 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** GNbAC1
- **BIOLOGICAL:** GNbAC1 placebo

## Key facts

- **NCT ID:** NCT01699555
- **Lead sponsor:** GeNeuro Innovation SAS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2012-03
- **Final completion:** 2012-08
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2020-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01699555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01699555, "First-in-Human Study With GNbAC1 in Healthy Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01699555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*